Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer

This response-to-comments notice (A58954) references MolDX LCD L38816 (Minimal Residual Disease Testing for Cancer) and only provides administrative metadata (comment and notice periods) rather than coverage criteria. No actionable indications, limitations, frequency limits, or documentation requirements are contained here; review LCD L38816 directly to extract the clinical coverage criteria and claim documentation requirements.

"This document is a response-to-comments notice referencing MolDX LCD L38816 (Minimal Residual Disease Testing for Cancer) and contains only metadata about the comment and notice periods; it does no..."

Sign up to see full coverage criteria, indications, and limitations.